Table 2.
Demographical Data and Basic Hemostatic Test Results.
| İmatinib (n = 47) | Dasatinib (n = 15) | Nilotinib (n = 6) | P | |
|---|---|---|---|---|
| Age | 46 (18-68) | 48 (34-66) | 51.5 (30-59) | .98 |
| Gender (F/M) | 24/23 | 8/7 | 4/2 | .81 |
| Platelet (×103/µL), (159-388 × 103/µL) | 232 (103-387) | 267 (147-456) | 164 (145-353) | .37 |
| aPTT (22.8-32 sec) | 28 (20-32) | 27.5 (22-33) | 29.1 (24-33) | .58 |
| INR (0.8-1.2) | 1 (0.8-1.7) | 0.9 (0.8-1.1) | 1 (0.9-1) | .91 |
| vWF-Ag (50%-160%) | 134 (66-193) | 144.5 (104-196) | 129 (81-177) | .5 |
| TT (14-21 sec) | 16.4 (14.6-22.1) | 16.4 (10.2-20.2) | 15.3 (14.7-17.9) | .22 |
| Fibrinogen (180-350 mg/dL) | 308.6 (192-506) | 334.7 (254-506) | 328 (263-459) | .2 |
| Factor VIII (70%-150%) | 155 (81-287) | 175.5 (129-288) | 162 (82-202) | .2 |
Abbreviations: aPPT, activated partial thromboplastin time; INR, international normalized ratio; TT, thrombin time; vWF-Ag, von Willebrand factor antigen.